{"id":149076,"date":"2021-10-04T10:29:05","date_gmt":"2021-10-04T20:29:05","guid":{"rendered":"https:\/\/www.hawaii.edu\/news\/?p=149076"},"modified":"2021-10-05T16:36:54","modified_gmt":"2021-10-06T02:36:54","slug":"covid-civax-candidate-update","status":"publish","type":"post","link":"https:\/\/www.hawaii.edu\/news\/2021\/10\/04\/covid-civax-candidate-update\/","title":{"rendered":"COVID-19 vaccine candidate exhibits broad response against variants"},"content":{"rendered":"Reading time: <\/span> 2<\/span> minutes<\/span><\/span>
\"two
PhD Researcher Albert To, left, with Lehrer in the lab.<\/figcaption><\/figure>\n

A heat-stable COVID-19 candidate developed by University of Hawaiʻi<\/span> at M\u0101noa researchers and the private sector has demonstrated broad-spectrum neutralizing antibody responses against the Beta, Gamma and Delta variants. <\/p>\n

\"Axel
Axel Lehrer<\/figcaption><\/figure>\n

糖心Vlog官方<\/abbr> M\u0101noa Associate Professor Axel Lehrer <\/strong>and lab colleagues in the John A. Burns School of Medicine<\/a>, and late-stage biopharmaceutical company Soligenix, Inc.<\/a> collaborated on advanced preclinical immunogenicity research that was recently posted as a preprint on bioRxiv<\/em><\/a> in the article, Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1<\/em>.<\/p>\n